The Gastrointestinal Safety of Orforglipron, a GLP‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials
Ahmed W. Hageen, Ahmed Farid Gadelmawla, Ahmad Omar Saleh, Abdallfatah Abdallfatah, Mohamed Reyad Mohamed, Amira Fahmy El‐Nemr, Odai Maihoub, Ahmed Elsekhary, Safir Eladawi, Biruk Demisse Ayalew, Ahmed Mansour, Ayoup Ahmed Radi, Mohamed Abuelazm, Mohamed Galal Flefel · 2026
Read The Gastrointestinal Safety of Orforglipron, a GLP‐1 Receptor Agonist, in Adults With or Without Type 2 Diabetes: A Network Meta‐Analysis of Randomized Controlled Trials by Ahmed W. Hageen, Ahmed Farid Gadelmawla, Ahmad Omar Saleh, Abdallfatah Abdallfatah, Mohamed Reyad Mohamed, Amira Fahmy El‐Nemr, Odai Maihoub, Ahmed Elsekhary, Safir Eladawi, Biruk Demisse Ayalew, Ahmed Mansour, Ayoup Ahmed Radi, Mohamed Abuelazm, Mohamed Galal Flefel (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13161550.txt.
Description
Orforglipron is a daily pill that mimics the gut hormone GLP-1, helping weight and blood sugar, but stomach side effects shadow the whole drug class. Ahmed Hageen and co-authors gather every randomized trial of the drug and compare its gut safety across doses in a network meta-analysis, which ranks treatments that were never tested head-to-head. Adults with and without type 2 diabetes were included.
Every dose, from 3 to 45 milligrams, raised gut side effects over placebo, and the climb was dose-shaped. At the top dose, nausea odds ran about eleven times placebo, vomiting and dropout due to gut effects also rose sharply, and diarrhoea odds were about fourfold. Pancreatitis did not increase at any dose. Liver enzyme ALT actually improved at higher doses, while pancreatic enzymes lipase and amylase rose without matching illness. The authors judge the profile in line with injectable drugs of the same class.
Catalog record
| CREATOR | Ahmed W. Hageen, Ahmed Farid Gadelmawla, Ahmad Omar Saleh, Abdallfatah Abdallfatah, Mohamed Reyad Mohamed, Amira Fahmy El‐Nemr, Odai Maihoub, Ahmed Elsekhary, Safir Eladawi, Biruk Demisse Ayalew, Ahmed Mansour, Ayoup Ahmed Radi, Mohamed Abuelazm, Mohamed Galal Flefel |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |